Ivy Brain Tumor Center at The Barrow Neurological Institute has launched a program that offers phase 0 trials to accelerate the drug approval process for patients with glioblastoma.
In this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Nader Sanai an internationally-recognized neurosurgical oncologist with clinical and research expertise in the treatment of all brain tumors, including glioblastoma, the most aggressive cancer that begins within the brain.
In Bret Stetka's latest piece for the Scientific American, Dr. Nader Sanai weighs in on the challenges of treating glioblastoma and how our accelerated Phase 0/2 clinical trials are delivering new therapeutic options for patients facing the fight of their lives.
The Ivy Brain Tumor Center at Barrow Neurological Institute is taking a bold approach by using Phase 0 testing in patient clinical trials.
There's a glimmer of hope in treating the deadliest form of brain cancer, thanks to a drug trial happening right here in the Valley.
Senator John McCain recently died after fighting glioblastoma, the most aggressive and deadliest kind of brain tumor. Now, other patients whose brain tumors come back have a revolutionary new option for treatment.
A new Ivy Brain Tumor Center study finds that recently-approved drug ribociclib may be an important part of treatment for glioblastoma, one of the deadliest cancers in the world.
The Ben and Catherine Ivy Foundation, in partnership with the Barrow Neurological Institute in Phoenix, has awarded a $50 million grant to establish a new translational science program focusing on early-phase, pharmacodynamic- and pharmacokinetic-driven clinical trials for aggressive brain tumors.
In the last 30 years, a brain tumor expert says median survival has only increased by a few months. Now, a new brain tumor center program is fast-tracking patients into new therapies.
Thanks to a $50 million grant, Barrow Neurological Institute will create a new center to focus on finding a cure and improving outcomes for the deadliest form of brain cancer.